Gara Jalqabaatti › Kansa Endometiriyaalii › Minnesota › Minneapolis
Qorannoo klinikaalii Kansa Endometiriyaalii Minneapolis, MN keessatti
Qorannoo 18 Kansa Endometiriyaalii f Minneapolis fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Namoota walitti qabaa jiraSadarkaa 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · Miili 5 fagaatti
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · Miili 5 fagaatti
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- Health Partners Frauenshuh Cancer Center, Saint Louis Park · Miili 5 fagaatti
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Namoota walitti qabaa jiraSadarkaa 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · Miili 5 fagaatti
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Namoota walitti qabaa jiraSadarkaa 3
- Minnesota Oncology Hematology, PA ( Site 8003), Minneapolis
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Namoota walitti qabaa jiraSadarkaa 3
- USOR - Minnesota Oncology/ Minneapolis Clinic, Minneapolis
- USOR - Minnesota Oncology, Minneapolis
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Minneapolis
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Minnesota Masonic Cancer Center, Minneapolis
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Minnesota, Minneapolis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Minnesota/Masonic Cancer Center, Minneapolis
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Normunity Investigational Site, Minneapolis
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- M Health Fairview University of Minnesota Medical Center, Minneapolis
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Namoota walitti qabaa jiraSadarkaa 1/2
- M Health Fairview University of Minnesota Medical Center, Minneapolis
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Minneapolis
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Namoota walitti qabaa jiraSadarkaa 2
- 518, Minneapolis
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1
- University of Minnesota, Minneapolis
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Allina Health Cancer Institute, Minneapolis
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Namoota walitti qabaa jiraSadarkaa 2/3
- Minnesota Oncology Hematology, P.A., Minneapolis
Qorannoo Kansa Endometiriyaalii magaalota biroo keessatti
- Houston, TXQorannoo 68
- New York City, NYQorannoo 52
- Boston, MAQorannoo 50
- Arlington, VAQorannoo 39
- Nashville, TNQorannoo 38
- Los Angeles, CAQorannoo 34
- St. Louis, MOQorannoo 29
- Philadelphia, PAQorannoo 28
- San Antonio, TXQorannoo 27
- Chicago, ILQorannoo 25
- Columbus, OHQorannoo 25
- Queens, NYQorannoo 25
Qorannoo biroo Minneapolis keessatti
- Saree OljooQorannoo 27
- Kansara Qara'a Non-Small CellQorannoo 26
- Kansarii OvariiQorannoo 24
- Kansarii ProstateQorannoo 23
- Saree (Gosoota Hunda)Qorannoo 22
- Cufama OnneeQorannoo 21
- Dhibee QaraQorannoo 20
- Leukemia Myeloidii HamaaQorannoo 20
- Kansarii ColorectalQorannoo 19
- Dhibee ParkinsonQorannoo 17
- Dhibee Onneessaa fi DhiigaQorannoo 15
- Dhukkuba Arterii KoronariyaaQorannoo 13
Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.